Biotech KBPA101 - fully human monoclonal antibodies

welcome to Kenta Biotech and the leading product KBPA101

» imprint

Pioneering antibody therapies for
life-threatening infections

We are a biotech company focused on the discovery and development of novel, fully human monoclonal antibodies for the prevention and treatment of serious bacterial and viral infections in the hospital setting.

Kenta's MabIgX® technology for the generation and selection of an advanced class of fully human monoclonal antibodies (MAbs) combines the advantages of classical hybridoma technology with a unique specific heteromyeloma fusion cell line.

Kenta Biotech Ltd.
Wagistrasse 25
CH-8952 Zürich-Schlieren
Switzerland

Tel: +41 (0) 58 680 52 52
Fax: +41 (0) 58 680 52 51
info@kentabiotech.com

Content on this page requires a newer version of Adobe Flash Player.